Q1 · MEDICINE
Article
Author: Shehu, Erald ; Rodrigues, Matthew J. ; McAndrew, P. Craig ; Henley, Alan T. ; van Montfort, Rob L. M. ; Johnson, Louise D. ; Burke, Rosemary ; Hayes, Angela ; Carter, Michael ; Varela, Ana ; de Klerk, Selby ; Cheung, Kwai-Ming J. ; Woodward, Hannah L. ; Davis, Owen A. ; Collie, Gavin W. ; Lloyd, Matthew G. ; Pierrat, Olivier A. ; Hoelder, Swen ; Shetty, Kartika N. ; Bright, Michael D. ; Raynaud, Florence I. ; Le Bihan, Yann-Vai ; Gowan, Sharon ; Rossanese, Olivia W. ; Innocenti, Paolo ; Box, Gary M. ; Bellenie, Benjamin R. ; Liu, Manjuan ; Kirkin, Vladimir ; Talbot, Rachel
Deregulation of the transcriptional repressor BCL6 enables tumorigenesis of germinal center B-cells, and hence BCL6 has been proposed as a therapeutic target for the treatment of diffuse large B-cell lymphoma (DLBCL). Herein we report the discovery of a series of benzimidazolone inhibitors of the protein-protein interaction between BCL6 and its co-repressors. A subset of these inhibitors were found to cause rapid degradation of BCL6, and optimization of pharmacokinetic properties led to the discovery of 5-((5-chloro-2-((3R,5S)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one (CCT369260), which reduces BCL6 levels in a lymphoma xenograft mouse model following oral dosing.